Monopar Therapeutics stock falls 5.60 percent below its gettex close
Published on 10/20/2026 at 22:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPrice and analyst view
- Monopar Therapeutics stock stood 5.60 percent below the gettex close on October 20, 2026.
- MarketBeat reported a USD 122.00 average target from ten analysts on October 11, 2026.
- Monopar Therapeutics stock cost EUR 65.80 at Lang & Schwarz on October 20, 2026 at 10:10 p.m. CEST, 5.60 percent below the gettex close of October 12, 2026.
- The next earnings report is scheduled for November 12, 2026.
Monopar Therapeutics stock stood 5.60 percent below the gettex close of EUR 69.70 on October 12, 2026. The move puts the clinical-stage biotechnology company below its latest German trading reference while analyst expectations remain substantially higher. At Lang & Schwarz, Monopar Therapeutics traded at EUR 65.80 on October 20, 2026 at 10:10 p.m. CEST, down 5.60 percent against that gettex close.
Analysts see USD 122.00
MarketBeat reported on October 11, 2026 that ten analysts assigned Monopar a Moderate Buy consensus and an average 12-month target of USD 122.00. Against the Nasdaq price of USD 74.23 at 4:00 p.m. EDT on October 20, 2026, that target stands 64.31 percent above the share price.
The same MarketBeat report put the latest quarterly loss at USD 0.62 per share against a USD 0.64 consensus loss. The USD 0.02 difference represents a 3.13 percent smaller loss than expected, although the result remained negative.
Stock remains inside its yearly range
On Nasdaq, MNPR last traded at USD 74.23 on October 20, 2026 at 4:00 p.m. EDT. Its 52-week range was USD 50.07 to USD 124.82 on that date, leaving the price 40.52 percent below the high and 48.23 percent above the low.
Monopar carried a market capitalization of USD 498.2 million on October 20, 2026. The company develops radiopharmaceutical candidates for oncology and ALXN1840, an investigational treatment for Wilson disease, according to its investor-relations page.
November report is next
Monopar's investor-relations page lists the American Association for the Study of Liver Diseases meeting from November 5 to November 9, 2026. The next earnings report is scheduled for November 12, 2026, according to MetaCap.
Comparison with peers
Monopar Therapeutics: down 5.60 percent versus the gettex close, P/E minus 31.72, market capitalization USD 498.2 million.
Pfizer (NYSE, USD): up 2.34 percent on October 20, 2026, P/E 39.81, market capitalization USD 171.7 billion.
Iovance Biotherapeutics (NASDAQ, USD): up 4.57 percent on October 20, 2026, P/E minus 20.36, market capitalization USD 6.7 billion.
Euro price under the German close
The euro quotation places Monopar below the gettex close used for the German market comparison, while the USD 122.00 analyst average remains well above the Nasdaq price. The further course of trading is shown by the continuously updated real-time quote of Monopar Therapeutics stock.
Monopar Therapeutics stock facts
- Company: Monopar Therapeutics Inc.
- ISIN: US61023L2079
- Ticker: MNPR
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 20, 2026, 10:10 p.m. CEST): EUR 65.80
- Change versus gettex close: minus 5.60 percent
- German close (gettex, October 12, 2026): EUR 69.70
- Market capitalization: USD 498.2 million (as of October 20, 2026)
- 52-week range: USD 50.07-124.82 (as of October 20, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 12, 2026
Market context: Market report S&P 500.
